Comparison of pathvysion and poseidon HER2 fish assays in measuring HER2 amplification in breast cancer: A validation study

Monika Francz, Kristof Egervari, Laszlo Kardos, J. Tóth, Z. Nemes, J. Szántó, Zoltan Szollosi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aims: The current study was done as a validation study prior to setting up a clinical HER2 testing service using the new commercial Poseidon HER2 fluorescence in situ hybridisation (FISH) assay. However, it was felt that the experience of the authors of this study may be of interest to other laboratories when considering setting up a HER2 diagnostic facility. Methods: 122 patients who had been diagnosed with invasive breast cancer were selected. Immunolabelling with HercepTest, PathVysion and Poseidon FISH assays were carried out using tissue microarray blocks. Results: Concordance correlation coefficients showed near perfect agreement in average HER2 and centromere specific signal counts per cell and in the HER2/CEP17 ratios between the PathVysion and the Poseidon FISH assays. In addition, the κ measure showed perfect agreement (κ 0.9441, p

Original languageEnglish
Pages (from-to)341-346
Number of pages6
JournalJournal of Clinical Pathology
Volume63
Issue number4
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Validation Studies
Fluorescence In Situ Hybridization
Fishes
Breast Neoplasms
Centromere
Cell Count

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Comparison of pathvysion and poseidon HER2 fish assays in measuring HER2 amplification in breast cancer : A validation study. / Francz, Monika; Egervari, Kristof; Kardos, Laszlo; Tóth, J.; Nemes, Z.; Szántó, J.; Szollosi, Zoltan.

In: Journal of Clinical Pathology, Vol. 63, No. 4, 04.2010, p. 341-346.

Research output: Contribution to journalArticle

@article{e265107f705e4754b059d8550db84a97,
title = "Comparison of pathvysion and poseidon HER2 fish assays in measuring HER2 amplification in breast cancer: A validation study",
abstract = "Aims: The current study was done as a validation study prior to setting up a clinical HER2 testing service using the new commercial Poseidon HER2 fluorescence in situ hybridisation (FISH) assay. However, it was felt that the experience of the authors of this study may be of interest to other laboratories when considering setting up a HER2 diagnostic facility. Methods: 122 patients who had been diagnosed with invasive breast cancer were selected. Immunolabelling with HercepTest, PathVysion and Poseidon FISH assays were carried out using tissue microarray blocks. Results: Concordance correlation coefficients showed near perfect agreement in average HER2 and centromere specific signal counts per cell and in the HER2/CEP17 ratios between the PathVysion and the Poseidon FISH assays. In addition, the κ measure showed perfect agreement (κ 0.9441, p",
author = "Monika Francz and Kristof Egervari and Laszlo Kardos and J. T{\'o}th and Z. Nemes and J. Sz{\'a}nt{\'o} and Zoltan Szollosi",
year = "2010",
month = "4",
doi = "10.1136/jcp.2009.066852",
language = "English",
volume = "63",
pages = "341--346",
journal = "Journal of Clinical Pathology - Clinical Molecular Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",
number = "4",

}

TY - JOUR

T1 - Comparison of pathvysion and poseidon HER2 fish assays in measuring HER2 amplification in breast cancer

T2 - A validation study

AU - Francz, Monika

AU - Egervari, Kristof

AU - Kardos, Laszlo

AU - Tóth, J.

AU - Nemes, Z.

AU - Szántó, J.

AU - Szollosi, Zoltan

PY - 2010/4

Y1 - 2010/4

N2 - Aims: The current study was done as a validation study prior to setting up a clinical HER2 testing service using the new commercial Poseidon HER2 fluorescence in situ hybridisation (FISH) assay. However, it was felt that the experience of the authors of this study may be of interest to other laboratories when considering setting up a HER2 diagnostic facility. Methods: 122 patients who had been diagnosed with invasive breast cancer were selected. Immunolabelling with HercepTest, PathVysion and Poseidon FISH assays were carried out using tissue microarray blocks. Results: Concordance correlation coefficients showed near perfect agreement in average HER2 and centromere specific signal counts per cell and in the HER2/CEP17 ratios between the PathVysion and the Poseidon FISH assays. In addition, the κ measure showed perfect agreement (κ 0.9441, p

AB - Aims: The current study was done as a validation study prior to setting up a clinical HER2 testing service using the new commercial Poseidon HER2 fluorescence in situ hybridisation (FISH) assay. However, it was felt that the experience of the authors of this study may be of interest to other laboratories when considering setting up a HER2 diagnostic facility. Methods: 122 patients who had been diagnosed with invasive breast cancer were selected. Immunolabelling with HercepTest, PathVysion and Poseidon FISH assays were carried out using tissue microarray blocks. Results: Concordance correlation coefficients showed near perfect agreement in average HER2 and centromere specific signal counts per cell and in the HER2/CEP17 ratios between the PathVysion and the Poseidon FISH assays. In addition, the κ measure showed perfect agreement (κ 0.9441, p

UR - http://www.scopus.com/inward/record.url?scp=77950392428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950392428&partnerID=8YFLogxK

U2 - 10.1136/jcp.2009.066852

DO - 10.1136/jcp.2009.066852

M3 - Article

C2 - 19965795

AN - SCOPUS:77950392428

VL - 63

SP - 341

EP - 346

JO - Journal of Clinical Pathology - Clinical Molecular Pathology

JF - Journal of Clinical Pathology - Clinical Molecular Pathology

SN - 0021-9746

IS - 4

ER -